Aarti Drugs Limited

NSEI:AARTIDRUGS 株式レポート

時価総額:₹44.5b

Aarti Drugs マネジメント

マネジメント 基準チェック /44

We currently do not have sufficient information about the CEO.

主要情報

Prakash Patil

最高経営責任者

₹27.8m

報酬総額

CEO給与比率41.5%
CEO在任期間39.8yrs
CEOの所有権9.6%
経営陣の平均在職期間11.3yrs
取締役会の平均在任期間8.3yrs

経営陣の近況

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Sep 20
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Recent updates

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Sep 20
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Sep 05
Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

May 04
Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Feb 01
Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Jan 30
Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

May 17
Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

Nov 22
These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Aug 28
We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Aug 19
Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value

May 17
Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value

Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock

Apr 04
Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock

Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?

Mar 17
Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 02
Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?

Feb 17
What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?

Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio

Feb 04
Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio

What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?

Jan 22
What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?

Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07
Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth

If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late

Dec 23
If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late

Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly

Dec 08
Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 23
Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?

Nov 08
How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?

Here's What We Learned About The CEO Pay At Aarti Drugs Limited (NSE:AARTIDRUGS)

Oct 11
Here's What We Learned About The CEO Pay At Aarti Drugs Limited (NSE:AARTIDRUGS)

CEO報酬分析

Aarti Drugs の収益と比較して、Prakash Patil の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

₹2b

Jun 30 2024n/an/a

₹2b

Mar 31 2024₹28m₹12m

₹2b

Dec 31 2023n/an/a

₹2b

Sep 30 2023n/an/a

₹2b

Jun 30 2023n/an/a

₹2b

Mar 31 2023₹28m₹11m

₹2b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹2b

Jun 30 2022n/an/a

₹2b

Mar 31 2022₹31m₹10m

₹2b

Dec 31 2021n/an/a

₹2b

Sep 30 2021n/an/a

₹2b

Jun 30 2021n/an/a

₹2b

Mar 31 2021₹35m₹8m

₹3b

Dec 31 2020n/an/a

₹3b

Sep 30 2020n/an/a

₹2b

Jun 30 2020n/an/a

₹2b

Mar 31 2020₹19m₹7m

₹1b

Dec 31 2019n/an/a

₹1b

Sep 30 2019n/an/a

₹1b

Jun 30 2019n/an/a

₹888m

Mar 31 2019₹15m₹7m

₹898m

Dec 31 2018n/an/a

₹863m

Sep 30 2018n/an/a

₹887m

Jun 30 2018n/an/a

₹943m

Mar 31 2018₹14m₹7m

₹823m

報酬と市場: Prakash's total compensation ($USD331.14K) is about average for companies of similar size in the Indian market ($USD268.55K).

報酬と収益: Prakash's compensation has been consistent with company performance over the past year.


CEO(最高経営責任者

Prakash Patil (77 yo)

39.8yrs

在職期間

₹27,848,000

報酬

Mr. Prakash Moreshwar Patil has been the Chairman of the Board of Aarti Drugs Limited since April 2014. Mr. Patil has been the Managing Director of Aarti Drugs Limited since June 1, 2007 and serves as its...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Prakash Patil
Chairmanno data₹27.85m9.59%
₹ 4.3b
Harshit Savla
Joint MD & Executive Director21.6yrs₹25.54m4.71%
₹ 2.1b
Adhish Patil
CFO & COO12.3yrs₹11.44m1.23%
₹ 547.6m
Rushikesh Deole
Company Secretary & Compliance Officer5.6yrs₹1.17mデータなし
Harit Shah
Whole-Time Directorno data₹25.54m4.43%
₹ 2.0b
Uday Patil
Whole-Time Director24.1yrs₹3.35m0.055%
₹ 24.3m
Rashesh Gogri
MD & Executive Director10.2yrs₹25.54m4.61%
₹ 2.0b
Dhanaji Kakade
Vice President of Technicalno dataデータなしデータなし
Vishwa Savla
Managing Director of the Pinnacle Life Science Private Limitedless than a yearデータなし1.02%
₹ 454.5m

11.3yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: AARTIDRUGS's management team is seasoned and experienced (11.3 years average tenure).


取締役

名称ポジション在職期間報酬所有権
Prakash Patil
Chairman39.8yrs₹27.85m9.59%
₹ 4.3b
Harshit Savla
Joint MD & Executive Director37.8yrs₹25.54m4.71%
₹ 2.1b
Harit Shah
Whole-Time Director29.2yrs₹25.54m4.43%
₹ 2.0b
Uday Patil
Whole-Time Director24.1yrs₹3.35m0.055%
₹ 24.3m
Rashesh Gogri
MD & Executive Director12.3yrs₹25.54m4.61%
₹ 2.0b
Chandrakant Gogri
Chairman Emeritus12.3yrs₹43.00k1.86%
₹ 826.9m
Neha Gada
Independent Director2.5yrs₹155.00kデータなし
Sandeep Joshi
Additional Independent Directorless than a yearデータなしデータなし
Narendra Salvi
Non-Executive Director4.3yrs₹100.00kデータなし
Ankit Paleja
Independent Director3.1yrs₹215.00kデータなし
Bhaskar Thorat
Independent Director2.5yrs₹155.00kデータなし
Hasmukh Dedhia
Additional Independent Directorless than a yearデータなしデータなし

8.3yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: AARTIDRUGS's board of directors are considered experienced (8.3 years average tenure).